Acquisition & Bidding - Am Wajiski, former CEO of 23 andMe, won the bid to take over the company through a nonprofit she controls [1][2] - Wajiski's bid needs bankruptcy court approval [2] - Regeneron initially had the winning bid but later dropped out [2] Concerns & Legal Issues - Legal questions arose regarding data transfer and the need for new consents [1][4] - Congress was also looking into the matter, raising further questions [3] - Regeneron determined that the value wasn't worth the higher price due to these concerns [1] Potential Benefits - Regeneron believed access to genetic information could significantly advance the study of genetic diseases [3] - Data could potentially be used for finding medicines, especially for rare genetic diseases [4]
Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron
CNBC Televisionยท2025-06-16 11:06